Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
執行長
Blaise Coleman
員工
2931
國家
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
上市
0 Comments
分享你的想法
FAQ
Endo International 今天的股價是多少?▼
ENDPQ 目前價格為 $0 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Endo International 股價表現。
Endo International 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Endo International 的股票以代號 ENDPQ 進行交易。
Endo International 去年的營收是多少?▼
Endo International 去年的營收為 2.01BUSD。
Endo International 去年的淨利是多少?▼
ENDPQ 去年的淨收益為 -2.45BUSD。
Endo International 有多少名員工?▼
截至 April 01, 2026,公司共有 2,931 名員工。
Endo International 位於哪個產業?▼
Endo International從事於Professional, Scientific, and Technical Services產業。